{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:22:55Z","timestamp":1787768575471,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n The incidence of bladder cancers (BCs) is increasing day by day in both males and females with increased smoking. New treatment protocols are required due to the long follow-up times and high recurrence rates. CD47 (integrin-associated protein) is a membrane receptor that is effective in normal and pathophysiological events such as apoptosis, proliferation, adhesion, and immunity. Phagocytosis of both normal and tumor cells is prevented, by binding to the ligand signal regulatory protein-1 (SIRP-1)\u03b1 on macrophages. Anti-CD47 antibodies can eliminate the binding and may be effective in treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n The study included 194 cases with urothelial carcinoma (UC) who underwent transurethral resection (TUR) of the bladder and had been followed up for one year. Cytoplasmic and membranous staining was preferred for CD47-positive staining. Staining results were compared with tumor grades, pathologic tumor stage, recurrence, and metastasis grade.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The prevalence and intensity of CD47 staining in BCs were evaluated in this study. High-grade tumors were stained more pronouncedly compared with low-grade tumors and normal epithelium. The prevalence of CD47 staining was significant in pT2 (Pathological tumor stage 2, invades of muscularis propria) tumors, and its correlation with pTa (Pathological tumor stage a, noninvasive papillary carcinoma) tumors was significant (\n P<\/jats:italic>\n < 0.001). In the intensity evaluation, there was a significant difference between pTa and pT2 and between pT1 (Pathological tumor stage 1, invades lamina propria) and pT2 (\n P<\/jats:italic>\n = 0.003).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n CD47 is expressed strongly in high-grade tumors. The prevalence and intensity of CD47 staining are high in pathologic tumor stage, recurrence, and distant metastases and are considered poor prognostic markers. We believe that anti-CD47 antibodies can be used as an alternative to the current treatment or in combination with other medications, and the systemic side effects that may occur with intravesical treatment can be prevented.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijc.ijc_644_21","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T07:00:37Z","timestamp":1702278037000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["CD47 expression in urothelial carcinoma and its correlation with histopathological findings"],"prefix":"10.4103","author":[{"given":"Ganime","family":"\u00c7oban","sequence":"first","affiliation":[{"name":"Department of Pathology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pelin","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[{"name":"Department of Pathology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevper","family":"Ers\u00f6z","sequence":"additional","affiliation":[{"name":"Department of Urology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Toprak","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurcan","family":"\u00dcnver","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eahande","family":"Elag\u00f6z","sequence":"additional","affiliation":[{"name":"Department of Pathology, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer \u0131ncidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"R4-20240828","article-title":"GLOBOCAN 2012 v1.0: Estimated cancer incidence, mortality, and prevalence worldwide in 2012","author":"Ferlay","year":"2013","journal-title":"\u0130nternational Agency for Research on Cancer"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-Cd47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0906549106","article-title":"Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells","volume":"16","author":"Chan","year":"2009","journal-title":"PNAS"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-03-1708","article-title":"CD47 mediates the killing of breast tumor cells via Gi-dependent inhibition of protein kinase A","volume":"64","author":"Manna","year":"2004","journal-title":"Cancer Res"},{"key":"R10-20240828","first-page":"9075","article-title":"CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma","volume":"15","author":"Ye","year":"2018","journal-title":"Oncol Lett"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6156757","article-title":"CD47 Blockade \u0131nhibits tumor progression through promoting phagocytosis of tumor cells by M2 polarized macrophages in endometrial cancer","volume":"1","author":"Gu","year":"2018","journal-title":"J Immunol Res"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s12094-016-1489-x","article-title":"CD47: A potential immunotherapy target for eliminating cancer cells","volume":"18","author":"Kong","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1083\/jcb.130.3.503","article-title":"Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1","volume":"130","author":"Bornstein","year":"1995","journal-title":"J Cell Biol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jmb.2007.10.085","article-title":"Structural insight into the specific interaction between murine SHPS-1\/SIRP alpha and its ligand CD47","volume":"375","author":"Nakaishi","year":"2008","journal-title":"J Mol Biol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRP\u03b1pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"R18-20240828","first-page":"157","article-title":"Changes in expression of differentiation markers between normal ovarian cells and derived tumors","volume":"142","author":"Van","year":"1993","journal-title":"Am J Pathol"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/cam4.478","article-title":"CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer","volume":"4","author":"Yoshida","year":"2015","journal-title":"Cancer Med"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/glia.21102","article-title":"Activation of CD47 receptors causes the proliferation of human astrocytoma but not normal astrocytes via an Akt-dependent pathway","volume":"59","author":"Sick","year":"2011","journal-title":"Glia"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/cc.10.1.14324","article-title":"CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2","volume":"10","author":"Kaur","year":"2011","journal-title":"Cell Cycle"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MOU.0b013e32833cc9df","article-title":"Cancer stem cells in bladder cancer: A revisited and evolving concept","volume":"20","author":"Chan","year":"2010","journal-title":"Curr Opin Urol"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1159\/000492652","article-title":"Prognostic \u0131mplication of urothelial stem cell markers differs according to primary tumour location in non-muscle-\u0131nvasive bladder cancer","volume":"48","author":"Wang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"R24-20240828","first-page":"349","article-title":"Relationship between immunohistochemical staining extent of CD47 and histopathologic features of bladder tumor","volume":"70","author":"Olcucuoglu","year":"2017","journal-title":"Cent European J Urol"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP axis","volume":"76","author":"Weiskopf","year":"2017","journal-title":"Eur J Cancer"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","article-title":"Molecular pathways: Activating T cells after cancer cell phagocytosis from blockade of Cd47 \u201cDon't Eat Me\u201dsignals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrinassociated protein (CD47) and its ligands","volume":"11","author":"Brown","year":"2011","journal-title":"Trends Cell Biol"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_644_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:15:20Z","timestamp":1787768120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.ijc_644_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":28,"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_644_21","relation":{},"ISSN":["0019-509X","1998-4774"],"issn-type":[{"value":"0019-509X","type":"print"},{"value":"1998-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]},"assertion":[{"value":"2021-05-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}